Osaka, Japan – June 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the transfer of manufacturing and marketing approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 5 mg* (generic name: zolmitriptan), a migraine treatment, as previously announced the conclusion of an agreement with AstraZeneca (Head Office: Cambridge, the UK; CEO: Pascal Soriot) on October 4, 2017. These products will be on sale on July 2, 2018.
* The “RM” in Zomig® RM is an acronym for “Rapid Melt.” Although this product is administered orally, as are other drugs, it is a preparation designed to melt quickly in the mouth, due to the actions of disintegrating and foaming agents within the product, whether taken with or without water.
Products for which the rights of manufacturing and marketing approval have been acquired
| Therapeutic category | Migraine treatment / 5-HT1B/1D receptor agonist |
|---|---|
| Name of the product | Zomig® Tablets 2.5 mg Zomig® RM Tablets 2.5 mg |